SEONGDONG-GU, SEOUL, SOUTH KOREA, January 5, 2023 /EINPresswire.com
/ — MDimune Inc., a Korean biotech firm growing BioDrone™ platform expertise primarily based on cell-derived vesicles (CDVs), introduced the publication of information within the Journal of Extracellular Biology displaying the event of the Good Manufacturing Follow (GMP)-compliant manufacturing technique of CDVs and their organic actions.
CDVs are nanosized vesicles, just like extracellular vesicles (EVs), produced from various human cells through the use of a proprietary extrusion methodology. Within the publication entitled “GMP-compliant manufacturing of biologically energetic cell-derived vesicles produced by extrusion expertise,” the corporate confirmed that its extrusion methodology can produce nanovesicles with extremely comparable bodily, biochemical, and useful properties to EVs, however at 10-100 instances increased yield than pure EVs. This demonstrates its distinct benefit in producing nanovesicles at scale.
The present work not solely escalated the size of the extrusion course of but additionally proved that CDVs may be manufactured in a GMP-compliant surroundings. Through the use of umbilical cord mesenchymal stem cells (UCMSCs), greater than ten thousand nanovesicles may be obtained per single cell, which far exceeds the productiveness of naturally secreted EVs. Furthermore, UCMSC-derived CDVs exhibited robust immunomodulatory potentials, akin to inhibition of T-cell proliferation and elevated exercise of CD73 which is thought for its anti-inflammatory impact, indicating that UCMSC-CDVs can be utilized to deal with many inflammatory illnesses.
Beforehand, MDimune confirmed the therapeutic impact of MSC-CDVs in varied illness fashions, akin to emphysema, spinal cord injury, stroke, cardiac harm, inflammatory bowel illness, and so on. With these pre-clinical findings and manufacturability examined in a GMP setting, MDimune is on monitor to maneuver its well-characterized MSC-CDVs ahead for scientific research within the coming 12 months.
“We’re delighted to publish this work of greater than two years of profitable collaboration,” mentioned Seung Wook Oh, Chief Scientific Officer at MDimune. “By establishing a GMP-compliant manufacturing course of at excessive yield, we’re getting nearer to testing our merchandise in scientific settings and finally for commercialization.”
Presently, MDimune is increasing trade partnerships with these corporations who want to make the most of the BioDrone™ platform for next-generation cell therapies or focused payload supply.
MDimune, Inc. http://www.mdimune.com/, https://biodroneus.com/
BioDrone™ Platform Expertise: https://youtu.be/lwwDQOpyKs4